Eisai Pipeline

For a list of Chugai's current research projects please visit: http://www.chugai-pharm.co.jp/engl...

Inheriting the research from the parent company – Chugai Technos Corporation in Japan, we would l...

Description/ Summary: Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antib...

Chugai's development pipeline is categorized to Oncology, Neuroscience, Hematology, Ophthalmology...

Chugai Pharmaceutical experienced unexpected demand for the drug Actemra during the pandemic, but...